Universe Pharmaceuticals Inc revenue

Universe Pharmaceuticals Inc's revenue was $17.86bn in fiscal 2025, down 22.4% on the year before. Since fiscal 2019 ($33.2m) it has grown at a compound 185.1% a year.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Universe Pharmaceuticals Inc: revenue history, annual
Fiscal year	2019Sept 2019	2020Sept 2020	2021Sept 2021	2022Sept 2022	2023Sept 2023	2024Sept 2024	2025Sept 2025
Revenue	0.0	0.0	0.0	0.0	32.3	23.0	17.9
Growth on the year before	—	−7.6%	+56.3%	−16.3%	+>999%	−28.7%	−22.4%
Gross profit	0.0	0.0	0.0	0.0	10.3	6.1	6.3
Gross margin	40.3%	45.9%	52.8%	54.5%	31.9%	26.4%	35.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Universe Pharmaceuticals Inc	$17.86bn	-22.4%	—
Viatris	$14.74bn	4.4%	-1.9%
Haleon plc	$14.55bn	1.3%	—
Bausch Health Companies Inc.	$11.11bn	10.8%	9.2%
Zoetis	$9.52bn	1.5%	5.0%
GSK plc	$43.09bn	7.5%	—

Compare with peers

Head to head: UPC vs VTRS HLN vs UPC BHC vs UPC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Universe Pharmaceuticals Inc's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Universe Pharmaceuticals Inc.